[1] |
刘秋月. 血凝试验检测结果质量的影响因素及改善对策分析[J]. 实用医技杂志, 2017, 24(6):641-643.
|
[2] |
Clinical and Laboratory Standards Institute. One-stage prothrombin time(PT) test and activated partial thromboplastin time(APTT) test[S]. H47-A2,CLSI, 2008.
|
[3] |
DOUGLAS A, TRIPLETT. Laboratory evaluation of coagulation[M]. Chicago: Amer Society of Clinical Press, 1982.
|
[4] |
ELAINE M K, CATHERINE N O, JEANINE M W. Rodak's hematology:clinical principles and applications[M]. 5th edition. Ashland: Saunders, 2015.
|
[5] |
SALANI R, BRISTOW R E. Surgical management of epithelial ovarian cancer[J]. Clin Obstet Gynecol, 2012, 55(1):75-95.
DOI
PMID
|
[6] |
王威, 袁莉, 何晓璇, 等. 试剂因子敏感性差异导致APTT室间质量评价失控分析[J]. 检验医学, 2018, 33(12):1136-1139.
|
[7] |
中华医学会风湿病学分会. 抗磷脂综合征诊断和治疗指南[J]. 中华风湿病学杂志, 2011, 15(6):407-410.
|
[8] |
FANGTHAM M, PETRI M. 2013 Update:Hopkins lupus cohort[J]. Curr Rheumatol Rep, 2013, 15(9):360.
DOI
URL
|
[9] |
PENGO V, TRIPODI A, REBER G, et al. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haemost, 2009, 7(10):1737-1740.
DOI
URL
|
[10] |
付璐, 李洁, 董丽梅, 等. 3种APTT试剂对LA的初筛价值[J]. 检验医学, 2019, 34(9):841-843.
|
[11] |
RASMUSSEN K L, PHILIPS M, TRIPODI A, et al. Unexpected,isolated activated partial thromboplastin time prolongation:a practical mini-review[J]. Eur J Haematol, 2020, 104(6):519-525.
DOI
URL
|
[12] |
RATANO D, ALBERIO L, DELODDER F, et al. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin[J]. Thromb Res, 2019, 175:53-58.
DOI
PMID
|
[13] |
HIRSH J, RASCHKE R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J]. Chest. 2004, 126(3 Suppl):188S-203S.
DOI
PMID
|
[14] |
EIKELBOOM J W, HIRSH J. Monitoring unfractionated heparin with the aPTT:time for a fresh look[J]. Thromb Haemost, 2006, 96(5):547-552.
DOI
URL
|